Patents Issued in March 21, 2024
-
Publication number: 20240091308Abstract: The present invention provides pea protein and compositions comprising pea protein for use in the prevention and/or treatment of autoimmune arthritis. The invention also provides said compositions for use in combination therapy with an antirheumatic drug. The invention also provides compositions comprising pea protein, alpha-glucooligosaccharide, acacia gum, and an antirheumatic drug, and their use as a medicament. The compositions of the invention are particularly useful for treating rheumatoid arthritis.Type: ApplicationFiled: May 15, 2023Publication date: March 21, 2024Applicant: DEVINTEC SAGLInventors: Miguel Angel Alonso Cohen, Rossana Sidoti, Bhavna Karnani
-
Publication number: 20240091309Abstract: Synthetic antimicrobial peptides, compositions comprising thereof, and methods of use for modulating one or more symptoms of an infection in a subject are disclosed. In some aspects, the infection is caused by mycobacteria, for example, a nontuberculous mycobacterium such as Mycobacterium abscessus. In other aspects, the infection is caused by Escherichia coli, Pseudomonas aeruginosa, or methicillin-resistant Staphylococcus aureus (MRSA). Also disclosed are methods of identifying synthetic antimicrobial peptides against a pathogen with no known effective treatment using a library of synthetic peptides.Type: ApplicationFiled: September 11, 2023Publication date: March 21, 2024Applicant: Arizona Board of Regents on Behalf of Arizona State UniversityInventors: Shelley HAYDEL, Christopher DIEHNELT
-
Publication number: 20240091310Abstract: Novel methods and pharmaceutical composition or medicaments are described for protecting a subject against, or treating a subject suffering from, disease characterised by viral infection and/or diseases associated with immune system disorder and/or viral cancers, by raising the levels of Ksp37 in the blood plasma of the subject to a therapeutically effective concentration level. According to the invention, a therapeutically effective amount of one or more of; a clinically modified or genetically engineered Ksp37 protein and/or proteins having a molecular weight in the range ranging from 24 kDa to 45 kDa, and/or a vector encoded with a KSP37 gene which will translate to a Ksp37 protein and/or proteins having a molecular weight in the range ranging from 24 kDa to 45 kDa, and/or a polar compound are administered to a subject.Type: ApplicationFiled: July 9, 2021Publication date: March 21, 2024Inventor: Michelle Olga Patricia Giesteira Da Silva SMIT
-
Publication number: 20240091311Abstract: The present invention relates to the field of treatment of ocular pathologies by administration of a NGF, which comprises more than 50% by weight of the NGF isoform of SEQ ID NO: 1. Said NGF is particularly useful in the treatment of ocular pathologies where the proliferation and survival effect of NGF is desired and where the proapoptotic effect of p75NTR is detrimental.Type: ApplicationFiled: February 4, 2022Publication date: March 21, 2024Inventors: Andrea ARAMINI, Pier Giorgio AMENDOLA, Anna SIRICO, Gaetano D'ANNIBALLE, Franca CATTANI, Marcello ALLEGRETTI, Flavio MANTELLI
-
Publication number: 20240091312Abstract: The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as pancreatic cancer and metastases thereof.Type: ApplicationFiled: August 24, 2023Publication date: March 21, 2024Inventors: Ugur Sahin, Özlem Türeci, Rita Mitnacht-Kraus, Stefan Wöll, Stefan Jacobs, Cornelia Heinz
-
Publication number: 20240091313Abstract: The present invention provides modified Vasoactive Intestinal Peptides (VIPs), encoding polynucleotides and vectors, as well as pharmaceutical compositions comprising the same. The invention further provides methods of making and using the modified VIP agents. In accordance with the invention the VIP exhibits an extended circulatory half-life, receptor-binding or biological potency, and/or altered receptor binding profile with respect to unmodified VIP.Type: ApplicationFiled: May 2, 2023Publication date: March 21, 2024Inventors: Homayoun SADEGHI, Suzanne DAGHER, Andrew TURNER
-
Publication number: 20240091314Abstract: The present invention provides methods for preventing, treating, or reducing the severity of sepsis, severe sepsis or septic shock, including bacterial, viral, and fungal infections, and including infections of more complex etiology. The invention involves the administration of an alpha thymosin peptide regimen. In certain embodiments, the alpha thymosin peptide regimen is scheduled or timed with respect to potential, expected and/or diagnosed sepsis, severe sepsis or septic shock. In certain embodiments, the patient is immunodeficient or immunocompromised, and/or the patient is hospitalized or scheduled for hospitalization, such that the regimen of alpha thymosin peptide peptide helps to protect the patient from, or reduce the severity of, sepsis, severe sepsis or septic shock.Type: ApplicationFiled: September 13, 2023Publication date: March 21, 2024Inventors: Xiangdong GUAN, Jianfeng WU, Cynthia W. TUTHILL
-
Publication number: 20240091315Abstract: The present invention relates to extended recombinant polypeptide (XTEN) compositions, conjugate compositions comprising XTEN and XTEN linked to cross-linkers useful for conjugation to pharmacologically active payloads, methods of making highly purified XTEN, methods of making XTEN-linker and XTEN-payload conjugates, and methods of using the XTEN-cross-linker and XTEN-payload compositions.Type: ApplicationFiled: March 13, 2023Publication date: March 21, 2024Inventors: Volker Schellenberger, Vladimir Podust, Chia-Wei Wang, Bryant McLaughlin, Bee-Cheng Sim, Sheng Ding, Chen Gu
-
Publication number: 20240091316Abstract: The present application relates to novel methods for preventing, slowing the progression of, or treating nonalcoholic fatty liver (NAFL), nonalcoholic steatohepatitis (NASH), and/or liver fibrosis, and/or reducing the risks of liver cancer in subjects, such as HIV-infected subjects, using a GHRH molecule, e.g., trans-3-hexenoyl-GHRH(1-44)-NH2, or a pharmaceutically acceptable salt thereof. The subjects may have particular pathological features such as liver fibrosis, a hepatic fat fraction (HFF) of at least about 10%, serum alanine aminotransferase (ALT) levels of at least about 30 U/L, and/or a NAFLD Activity Score (NAS) of at least 4 or 5.Type: ApplicationFiled: July 12, 2023Publication date: March 21, 2024Applicant: The General Hospital CorporationInventor: Steven K. GRINSPOON
-
Publication number: 20240091317Abstract: The present invention relates to dosage regimes for the administration of glucagon-like-peptide-2 (GLP-2) analogues, and in particular to ZP1848 (glepaglutide), in patients with renal insufficiency. Unlike other GLP-2 analogues, such as teduglutide, it has been found that ZP1848 is cleared normally in patients with renal impairment. As a result, there is no need to adjust the dosage of ZP1848 depending on a patient's renal function.Type: ApplicationFiled: December 15, 2021Publication date: March 21, 2024Inventors: Kim SONNE, Mikkel Askjær AGERSNAP, Kim Mark KNUDSEN
-
Publication number: 20240091318Abstract: A combination therapy is provided, which comprises Compound I (GLP-1R/glucagon receptor dual agonist): H-His-Ac4c-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Glu-Arg-Ala-Ala-Lys-Asp-Phe-Ile-Lys(HOOC—(CH2)16-CO-?Glu-Gly-Ser-Gly-Ser-Gly-Gly-)-Trp-Leu-Glu-Ser-Ala-NH2 (I) and a long acting NPY2 receptor agonist selected from Compound A to L. The combination therapy might be useful to treat obesity and various obesity-related conditions, diseases, or co-morbidities, such as type 2 diabetes, liver diseases such as NAFLD (non-alcoholic fatty liver disease) and NASH (non-alcoholic steatohepatitis), kidney diseases, or cardiovascular diseases.Type: ApplicationFiled: August 16, 2023Publication date: March 21, 2024Inventors: Robert AUGUSTIN, Anouk OLDENBURGER
-
Publication number: 20240091319Abstract: A method of treating a patient having edematous lungs includes: administering a first surface tension-lowering component to the patient via the airways and administering a second surface tension-lowering component to the patient via the vasculature. The combined and complementary treatments may lower or normalize alveolar surface tension with improved efficiency and on a faster timescale, thereby reducing patient injury and mortality (FIG. 1).Type: ApplicationFiled: January 18, 2022Publication date: March 21, 2024Applicant: THE TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOGYInventor: Carrie E. PERLMAN
-
Publication number: 20240091320Abstract: The present invention relates to a peptide with anti-inflammatory activity, wherein the peptide comprises SEQ ID NO: 1, the peptide has above 80% homology of amino acid sequence with above-mentioned sequence, or the peptide is the fragment of the above-mentioned peptides. The present invention also relates to an inflammatory composition comprising the above mentioned peptides. According to the present invention, a peptide comprising a sequence of SEQ ID NO: 1 has an outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising the peptide of this invention can be used as anti-inflammatory pharmaceutical composition or as cosmetic composition, in turn, treating and preventing a variety of different types of inflammatory diseases.Type: ApplicationFiled: August 9, 2023Publication date: March 21, 2024Inventors: Sang Jae KIM, Kyung Hee KIM, Kyu-Yong LEE, Seong-Ho KOH, Hyun-Hee PARK, Sung Jin HUH, Woo Jin LEE, Bum Joon KIM
-
Publication number: 20240091321Abstract: Provided herein are novel IGF2 peptides, fusion proteins, and nucleic acid sequences encoding novel IGF2 peptides and fusion proteins for the treatment of lysorsomal storage disorders, wherein the IGF2 peptides confer enhanced properties, such as enhanced expression, secretion and cellular uptake. The constructs provided herein are useful in treating lysosomal storage disorders by both enzyme replacement therapy and gene therapy.Type: ApplicationFiled: October 12, 2020Publication date: March 21, 2024Applicant: Amicus Therapeutics, Inc.Inventors: Hung V. Do, Steven Tuske, Russell Gotschall, Ce Feng Liu
-
Publication number: 20240091322Abstract: Provided is a protein complex including a botulinum toxin translocation domain and endolysin. When used, the protein complex including a botulinum translocation domain and endolysin according to the present invention exhibits an antibacterial effect and thus can be used as an antibacterial composition or an antibiotic.Type: ApplicationFiled: April 18, 2022Publication date: March 21, 2024Applicant: MVRIX Co., Ltd.Inventors: Dae Hyuk KWEON, Wonbeom PARK, Jihwan CHUN
-
Publication number: 20240091323Abstract: Disclosed herein are ACE2 recombinant proteins and methods of using such for therapeutic and/or diagnostic purposes. Also provided herein are methods for producing such recombinant proteins.Type: ApplicationFiled: January 7, 2022Publication date: March 21, 2024Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMInventors: Daniel M. Rosenbaum, Daniel Kober
-
Publication number: 20240091324Abstract: The present invention relates to a composition for improving gastrointestinal health comprising bromelain enzyme, short-chain fatty acids, specified amino acids, and vitamin D.Type: ApplicationFiled: October 9, 2020Publication date: March 21, 2024Applicant: Anatara Lifesciences LtdInventor: Tracey BROWN
-
Publication number: 20240091325Abstract: Provided are compositions and methods for enzyme replacement therapy using modified human cystathionine beta synthase (CBS) in the treatment of homocystinuria and related diseases and disorders.Type: ApplicationFiled: August 23, 2023Publication date: March 21, 2024Inventors: Jan P. Kraus, Tomas Majtan, Erez Bublil
-
Publication number: 20240091326Abstract: Ocular serpinA3 activity is modulated to treat glaucoma by neuroprotection, comprising administering to an eye in need thereof a serpinA3 polypeptide or a nucleic acid encoding the serpinA3 polypeptide.Type: ApplicationFiled: November 25, 2023Publication date: March 21, 2024Applicant: The Regents of the University of CaliforniaInventors: Lu Chen, Lingling Zhang
-
Publication number: 20240091327Abstract: Antigens of Toxoplasma gondii that provide specific and strong delayed type hypersensitivity (DTH) immune response, or which stimulate IFN-? secretion, are used for testing subjects for infection. Any skin testing format may be adapted for testing for the delayed type hypersensitivity, including a patch, a needle, or a prong. Presence of DTH indicates infection. Alternate methods of detecting a T cell response including monitoring IFN-? secretion may be used.Type: ApplicationFiled: September 8, 2023Publication date: March 21, 2024Inventors: Laurence David Sibley, Kevin M. Brown, Qiuling Wang, Iti Saraav
-
Publication number: 20240091328Abstract: The present disclosure provides compositions and methods for generating immune response or enhancing immune response. The method comprises administering to a subject in need of treatment a compositions comprising liposomes comprising porphyrins with cobalt chelated thereto such that the cobalt metal resides within the bilayer in the porphyrin macrocycle, and polyhistidine tagged MHC-I restricted tumor peptides.Type: ApplicationFiled: January 11, 2022Publication date: March 21, 2024Inventors: Jonathan LOVELL, Xuedan HE, Shiqi ZHOU
-
Publication number: 20240091329Abstract: Provided are compositions, optionally pharmaceutical compositions, that include a plurality of exosomes generated from stem cells, optionally ESCs and/or iPSCs, that have been modified to express a granulocyte-macrophage colony stimulating factor (GM-CSF) polypeptide, optionally a human GM-CSF polypeptide. Also provided are methods for employing the presently disclosed compositions for preventing and/or inhibiting tumor growth in subjects in need thereof, for preventing and/or inhibiting metastases in subject in need thereof, for inducing anti-tumor immune responses in subjects, and uses of the presently disclosed compositions for prevention and/or treatment of tumors and/or cancers and for the preparation of medicaments for treatment of tumors and/or cancers.Type: ApplicationFiled: June 12, 2023Publication date: March 21, 2024Applicant: University of Louisville Research Foundation, Inc.Inventors: John W Eaton, Kavitha Yaddanapudi, Chi Li
-
Publication number: 20240091330Abstract: The invention provides methods of modulating an immune system in a vertebrate host for the therapeutic or prophylactic treatment of infection by a first microbial pathogen in a target tissue, comprising administration at an administration site of an effective amount of an antigenic formulation comprising antigenic determinants specific for a second heterologous microbial pathogen.Type: ApplicationFiled: October 12, 2023Publication date: March 21, 2024Inventors: Harold David Gunn, Salim Dhanji, David W. Mullins
-
Publication number: 20240091331Abstract: The invention relates to compositions and peptides or peptide sequences that induce an immune response in an animal or a mammal that is protective against infection by one or more pathogens. In addition, the invention relates to immunogenic composition and vaccines comprising compositions and peptide sequences and to method for treating and preventing an infection in animals and mammals such as humans and antibodies.Type: ApplicationFiled: November 13, 2023Publication date: March 21, 2024Applicant: Longhorn Vaccines and Diagnostics, LLCInventors: Gerald W. Fischer, Clara J. Sei, Jeffrey D. Fischer
-
Publication number: 20240091332Abstract: The invention relates to compounds, compositions, and methods for biofilm disruption and prevention. In particular, the invention relates to pharmaceutical compositions for the disruption of biofilm and prevention of biofilm in patients. The invention also relates to anti-biofouling compositions for the disruption of biofilm and prevention of biofilm on surfaces. The invention also relates to the removal of biological material from surfaces. The compositions of the invention include microbial deoxyribonucleases.Type: ApplicationFiled: December 21, 2022Publication date: March 21, 2024Applicant: University of New Castle Upon TyneInventors: James Grant Burgess, Michael John Hall, Reindert Nijland
-
Publication number: 20240091333Abstract: Nucleic acid and the nanocomplex reagents are combined to create a vaccine. They are stable and stored separately without degradation. The vaccine components can be stored at a wide range of temperatures. The nucleic acids are stabilized and stored in a column, syringe, vial or chamber as a solid, lyophilized or precipitated. They may be stored on a solid phase surface through electrostatic forces, non-polar interactions, hydrogen bonding, polar interactions or any other mechanism. The solid surface may be media in a column which may be contained in a syringe. Nucleic acid vaccines are prepared by a two-step process. The nucleic acid component is first stabilized and then mixed with nanocomplex reagents, particle forming reagents or other reagents.Type: ApplicationFiled: December 28, 2021Publication date: March 21, 2024Inventor: Douglas T. Gjerde
-
Publication number: 20240091334Abstract: The present disclosure provides a combined vaccine against human respiratory syncytial virus (RSV) infection and a method thereof for inducing immune response. The combined vaccine includes; a first composition including an immunologically effective dosage of a replication-deficient human adenovirus type 26 vector contains a nucleotide encoding an antigenic protein of RSV and a pharmaceutically acceptable vector; and a second composition including an immunologically effective dosage of a replication-deficient chimpanzee adenovirus type 63 vector contains a nucleotide encoding an antigenic protein of RSV and a pharmaceutically acceptable vector. The first composition is a primary immunization composition and the second composition is a booster immunization composition, or vice versa. In the present disclosure, the combined vaccine is used for inducing a protective immunity against RSV infection, and a method is provided for generating the protective immunity against RSV infection.Type: ApplicationFiled: August 11, 2021Publication date: March 21, 2024Inventors: Jinsheng HE, Lin DU, Yuanhui FU, Weihua ZHU, Xianglei PENG, Bo GAO, Yanpeng ZHENG, Meiqin LIU
-
Publication number: 20240091335Abstract: The present invention provides the induction of novel Th1 response, the induction of cytotoxic T cells and anti-cancer/anti-allergic activity techniques. Provided is a combination of a CpG oligonucleotide and an STING agonist. Also provided is a composition which contains an STING agonist, can be used as a type-I adjuvant, and is characterized in that the STING agonist is administered together with a CpG oligonucleotide. Further provided is an anti-cancer agent comprising a CpG oligonucleotide and is characterized in that the CpG oligonucleotide is administered together with an STING agonist. Still further provided is a composition which contains a CpG oligonucleotide and can be used for reducing or eliminating the IgE-inducing activity of an STING agonist.Type: ApplicationFiled: August 25, 2023Publication date: March 21, 2024Inventor: Ken Ishii
-
Publication number: 20240091336Abstract: Immunogenic compositions for inducing a universal immune response to influenza, and particularly influenza A, by eliciting anti-neuraminidase antibodies which provide protection against heterologous influenza infection. Compositions comprising recombinant expression vectors expressing neuraminidase in cultured cells dispersed in a pharmaceutically-acceptable carrier comprising cell culture media, and optional adjuvant. Methods of inducing immune responses against influenza, and particularly influenza A, by eliciting anti-neuraminidase antibodies in a host animal susceptible to infection.Type: ApplicationFiled: September 29, 2023Publication date: March 21, 2024Inventor: Ben Hause
-
Publication number: 20240091337Abstract: Disclosed herein are compositions and methods related to mutant viruses, and in particular, mutant influenza viruses. The mutant viruses disclosed herein include a mutant BM2 sequence, and are useful in immunogenic compositions, e.g., as vaccines. Also disclosed herein are methods, compositions and cells for propagating the viral mutants, and methods, devices and compositions related to vaccination.Type: ApplicationFiled: December 2, 2022Publication date: March 21, 2024Applicant: FluGen, Inc.Inventors: Michael J. Moser, Yasuko Hatta, Pamuk Bilsel
-
Publication number: 20240091338Abstract: The present invention relates to administration regimens which are particularly suited for vaccine composition comprising polynucleotides which encode immunogenic polypeptides. Said administration regimens involve the repeated administration of a vaccine composition and enhance the immune response against the immunogenic polypeptide.Type: ApplicationFiled: February 28, 2023Publication date: March 21, 2024Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Alfredo Nicosia, Ricardo Cortese, Alessandra Vitelli
-
Publication number: 20240091339Abstract: The present invention relates generally to immunization and immunotherapy for the treatment or prevention of HIV. In particular, the methods include in vivo and/or ex vivo enrichment of HIV-specific CD4+ T cells.Type: ApplicationFiled: July 28, 2023Publication date: March 21, 2024Inventors: Charles David Pauza, Haishan Li, Tyler Lahusen, Gary Mansfield
-
Publication number: 20240091340Abstract: The present invention relates generally to immunization and immunotherapy for the treatment or prevention of HIV. In particular, the methods relate to in vivo and ex vivo enrichment of HIV-specific CD4 T cells. In certain embodiments, the disclosed compositions and methods can incorporate therapy in order to further enhance the HIV-specific CD4 T cells.Type: ApplicationFiled: July 28, 2023Publication date: March 21, 2024Inventor: Charles David Pauza
-
Publication number: 20240091341Abstract: The present invention provides a new component that is useful as a SARS-CoV-2 vaccine antigen that uses as a target a receptor binding domain of SARS-CoV-2. The present invention contains the fusion protein, which includes hemagglutinin and a receptor binding domain of SARS-CoV-2, and a vaccine containing the fusion protein.Type: ApplicationFiled: October 18, 2021Publication date: March 21, 2024Inventor: Yasuo YOSHIOKA
-
Publication number: 20240091342Abstract: Provided is an orally administrable vaccine against a coronavirus infectious disease. A transformed Bifidobacterium designed to display a part or a whole of a constituent protein of a coronavirus on a surface of the Bifidobacterium enables the provision of the orally administrable vaccine against a coronavirus infectious disease. The transformed Bifidobacterium designed to display a part or a whole of a constituent protein of a coronavirus on a surface of the Bifidobacterium can induce humoral immunity and cellular immunity through oral administration to suppress an increase in severity of pneumonia or the like even after viral infection.Type: ApplicationFiled: January 25, 2022Publication date: March 21, 2024Applicants: NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY, Kyoto UniversityInventors: Toshiro SHIRAKAWA, Shunpei UENO, Koichi KITAGAWA, Akihiko KONDO, Masanori KAMEOKA, Takane KATAYAMA
-
Publication number: 20240091343Abstract: Provided are a method for preparing an mRNA-LNP and use thereof, on which a technology platform of an uncapped-linear mRNA with unmodified uridine is based. The provided linear mRNA is composed of a 5? UTR including the IRES, a coding region and a poly A region has a simple structure and high stability and efficiency on its expression in vivo and in vitro. The uncapped-linear mRNA with unmodified uridine is then encapluslated by a new lipid nanoparticle (LNP-1) to form an mRNA-LNP.Type: ApplicationFiled: August 24, 2023Publication date: March 21, 2024Inventors: Binlei LIU, Linkang CAI, Peng NI
-
Publication number: 20240091344Abstract: The present invention relates to mRNAs suitable for use as mRNA-based vaccines against infections with MERS coronaviruses. Additionally, the present invention relates to a composition comprising the mRNAs and the use of the mRNAs or the composition for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of MERS coronavirus infections. The present invention further describes a method of treatment or prophylaxis of infections with MERS coronavirus using the mRNA sequences.Type: ApplicationFiled: November 20, 2023Publication date: March 21, 2024Applicant: CureVac SEInventor: Susanne RAUCH
-
Publication number: 20240091345Abstract: The present invention relates to a nucleic acid encoding a HSV2 Fc receptor or immunogenic fragment or variant thereof for use in generating a cross reactive immune response against HSV1 in a subject. Also provided is a nucleic acid encoding a HSV1 Fc receptor or immunogenic fragment or variant thereof for use in generating a cross reactive immune response against HSV2 when administered to a subject.Type: ApplicationFiled: January 18, 2022Publication date: March 21, 2024Applicant: GlaxoSmithKline Biologicals SAInventors: Johann MOLS, Marie TOUSSAINT
-
Publication number: 20240091346Abstract: Anti-Epstein Barr Virus (EBV) vaccines are described herein. The EBV vaccine antigens are linked to a multimerization domain, for example, presented on a circular tandem repeat protein (cTRP) scaffold or linked to a C4b multimerization domain. The vaccines can be used to treat and/or reduce the risk of EBV infection and to treat and/or reduce the risk of complications associated with EBV infection, such as infectious mononucleosis, lymphoproliferative disorders, carcinomas, and smooth muscle tumors.Type: ApplicationFiled: August 29, 2023Publication date: March 21, 2024Applicant: Fred Hutchinson Cancer CenterInventors: Jason Price, James M. Olson, Andrew McGuire, Barry L. Stoddard
-
Publication number: 20240091347Abstract: Provided herein are non-naturally occurring variants of the hepatitis B virus (HBV) Core protein, the HBV polymerase N-terminal domain, and the HBV polymerase C-terminal domain, as well as immunogenic fragments thereof. Fusion proteins comprising the HBV variants fused to a herpes simplex virus (HSV) glycoprotein (gD) sequence, as well as methods of using the fusion proteins, are also provided.Type: ApplicationFiled: October 24, 2023Publication date: March 21, 2024Inventors: Hildegund CJ ERTL, Colin Stephen MAGOWAN
-
Publication number: 20240091348Abstract: The present invention provides pharmaceutical compositions comprising particles formed by synthetic polymers and polyinosinic-polycytidylic acid and compositions comprising polyinosinic-polycytidylic acid having a specific size distribution, that are adapted for parenteral administration, in particular for subcutaneous, intramuscular, or intravenous injection or infusion. These formulations can be used in a variety of clinical applications, for instance, in methods for administering vaccines or for treating or preventing cancer. The disclosed formulations can be used in combination with conventional therapies such as radiation therapy, chemotherapy, immunotherapy, cryotherapy, tumor ablation and/or anti-cancer drugs or other standard-of-care medical treatments.Type: ApplicationFiled: July 11, 2023Publication date: March 21, 2024Applicant: HIGHLIGHT THERAPEUTICS, S.L.Inventors: Juan-Manuel FUNES, Mercedes POZUELO RUBIO, Marisol Quintero Ortiz
-
Publication number: 20240091349Abstract: Quil-A chitosan spherical nanostructure complexes as well as methods of making and using such complexes are disclosed herein. Also provided are Quil-A chitosan spherical nanostrucutres loaded with one or more RNA, DNA, or protein payload molecules as well as methods of making and using such loaded complexes.Type: ApplicationFiled: August 16, 2023Publication date: March 21, 2024Inventors: Adel M. Talaat, Shaswath Chandrasekar
-
Publication number: 20240091350Abstract: The present invention provides pharmaceutical compositions comprising polyinosinic-polycytidylic acid, in particular using particles formed by synthetic polymers, that are adapted for parenteral administration, such as for subcutaneous, intramuscular, or intravenous injection, or infusion. The formulations disclosed herein may be used in a variety of clinical applications, for instance, in methods for administering cell-, peptide-, or nucleic acid-based cancer vaccines or for administering other agents to treat or prevent cancer. The disclosed formulations may also be used in combination with conventional therapies such as radiation therapy, chemotherapy, immunotherapy, cryotherapy, tumor ablation and/or anti-cancer drugs or other standard-of-care medical treatments.Type: ApplicationFiled: September 18, 2023Publication date: March 21, 2024Applicant: HIGHLIGHT THERAPEUTICS, S.L.Inventors: Juan-Manuel FUNES, Mercedes POZUELO RUBIO, Marisol QUINTERO ORTIZ
-
Publication number: 20240091351Abstract: Provided are methods of treating, mitigating, reducing, preventing or delaying the growth, proliferation, recurrence or metastasis of a solid cancer in a mammalian subject in need thereof comprising co-administering to the subject an effective amount of radiation therapy (RT) focally-delivered to the solid cancer; and an agent that inhibits binding between CD47 and SIRP?.Type: ApplicationFiled: September 19, 2023Publication date: March 21, 2024Inventors: Hikmat H. Assi, Jamie G. Bates
-
Publication number: 20240091352Abstract: The present invention relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.Type: ApplicationFiled: February 28, 2023Publication date: March 21, 2024Inventors: Esther BREIJ, David SATIJN, Edward Norbert VAN DEN BRINK, Dennis VERZIJL, Rob N. DE JONG, Paul PARREN, Riemke VAN DIJKHUIZEN RADERSMA
-
Publication number: 20240091353Abstract: The present invention provides immunoresponsive cells, including T cells, cytotoxic T cells, regulatory T cells, and Natural Killer (NK) cells, expressing at least one of an antigen recognizing receptor and one of a chimeric costimulatory receptor. Methods of using the immunoresponsive cell include those for the treatment of neoplasia and other pathologies where an increase in an antigen-specific immune response is desired.Type: ApplicationFiled: June 13, 2023Publication date: March 21, 2024Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: Christopher C. Kloss, Michel Sadelain
-
Publication number: 20240091354Abstract: This provides pharmaceutical compositions that comprise a combination of an anti-cancer agent which is an first antibody and a second antibody. In some embodiments, the first antibody is an anti-Programmed Death-1 (PD-1) antibody. In certain embodiments, the composition is a fixed dose formulation. In certain embodiments, the composition is administered as a flat-dose. The disclosure also provides a kit for treating a subject afflicted with a disease, the kit comprising a dosage of any composition disclosed herein and instructions for using the composition in any of the disclosed methods for treating a disease.Type: ApplicationFiled: March 27, 2023Publication date: March 21, 2024Applicant: Bristol-Myers Squibb CompanyInventors: Vikram SADINENI, Yong QUAN, Wallace KASERER
-
Publication number: 20240091355Abstract: The present invention relates to a composition, for prevention or treatment of cancer diseases, comprising CD8+ T cells activated by CD4+ T cell-derived extracellular vesicles as an active ingredient. It was found that the secretion of extracellular vesicles from cytokine-activated CD4+ T cells increases and the extracellular vesicles enhance proliferation and activity of CD8+ T cells to induce the death of cancer cells, thereby augmenting an anticancer effect. Thus, the present invention provides the CD8+ T cells activated by CD4+ T cell-derived extracellular vesicles as a pharmaceutical agent or an immunotherapeutic agent for cancer diseases, and a method for activating CD8+ T cells by using CD4+ T cell-derived extracellular vesicles to prepare CD8+ T cells showing excellent anticancer activity as described above.Type: ApplicationFiled: September 18, 2020Publication date: March 21, 2024Applicants: KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, DAEGU GYEONGBUK INSTITUTE OF SCIENCE AND TECHNOLOGYInventors: Moon-Chang BAEK, Kyungmoo YEA, Do Kyung JUNG, Suyeon RYU, Sang Hee SHIN, In Seong JUNG
-
Publication number: 20240091356Abstract: Disclosed are compositions and methods for targeted treatment of myeloid and B cell malignancies. In particular, chimeric antigen receptor (CAR) T cells are disclosed that can be used with adoptive cell transfer to target and kill myeloid and B cell malignancies with reduced antigen escape. Therefore, also disclosed are methods of providing an anti-tumor immunity in a subject with a myeloid and B cell malignancies that involves adoptive transfer of the disclosed CAR T cells.Type: ApplicationFiled: January 14, 2022Publication date: March 21, 2024Inventor: Marco Davila
-
Publication number: 20240091357Abstract: The present invention relates to an engineered immune cell which comprises: (i) a target binding polypeptide comprising a target-binding domain and a first protein interaction domain, and (ii) a localising polypeptide comprising a second protein interaction domain, which binds to the first protein binding domain, and an intracellular retention signal. When the target binding polypeptide binds its target protein and also the localising polypeptide, expression of the target protein at the cell surface is reduced or eliminated because the target protein is retained in an intracellular compartment.Type: ApplicationFiled: October 9, 2020Publication date: March 21, 2024Inventors: Martin Pulé, Shaun Cordoba, Shimobi Onuoha, Simon Thomas, Thomas Grothier